Logo
x

Search

Subscribe Now

Disease

Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies

Vertex Signs a License Agreement with Obsidian Therapeutics to Discover Regulated Gene Editing Therapies

  • April 23, 2021
Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas

Schrödinger Signs a $2.7B Agreement with BMS to Develop and Commercialize Therapies in Multiple Disease Areas

  • November 24, 2020
Novartis's Branaplam (LMI070) Receives the US FDA's Orphan Drug Designation for Huntington's Disease

Novartis's Branaplam (LMI070) Receives the US FDA's Orphan Drug Designation for Huntington's Disease

  • October 22, 2020
Bayer's Lampit (nifurtimox) Receives the US FDA's Approval for Treatment of Chagas Disease in Children

Bayer's Lampit (nifurtimox) Receives the US FDA's Approval for Treatment of Chagas Disease in Children

  • August 7, 2020
Takeda's Entyvio (vedolizumab) Receives NMPA's Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease

Takeda's Entyvio (vedolizumab) Receives NMPA's Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease

  • March 23, 2020
Kyowa Kirin's Istradefylline (KW-6002) Receives EMA's MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Parkinson's disease Experiencing “Off” Time

Kyowa Kirin's Istradefylline (KW-6002) Receives EMA's MAA as an Adjunctive Treatment to Levodopa-Based Regimens in Adult with Park...

  • January 6, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.